Navigation Links
XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
Date:3/20/2008

cal trials, two of which, atazanavir for HIV, and entecavir for Hepatitis B, are currently approved drugs."

Ron Bentsur, XTL's CEO commented: "We are excited about this licensing transaction with a motivated and capable partner such as Presidio. This transaction allows us to solidify our financial position by bringing in $4 million dollars in cash and eliminating the ongoing development expense of the Program, while preserving a significant share in the Program's future success. We believe that this transaction extends our financial resources well into Q1 2009, and provides us with a financial cushion as we head towards the completion and announcement of results from the Bicifadine Phase 2b study, expected in Q4 2008."

The Program focuses on the development of novel small molecule inhibitors against the Hepatitis C virus, and is presently in advanced stages of lead optimization. The current lead compounds target NS5A - a viral protein that is essential for viral production. NS5A is distinct from the protease and polymerase. The Program's lead compounds are highly potent inhibitors of viral replication in the replicon assay, which is known to have good correlation with clinical efficacy and is currently the leading method for preclinical testing of inhibitors of the Hepatitis C Virus.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (NASDAQ:

SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
8. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
11. XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... September 2, 2015 ... die Forschung und Entwicklung neuartiger Therapien für ... Darmerkrankungen und Reizdarm konzentriert, erhält vom US ... sein neues Medikament patentiert wird. Das Medikament ... bei Kindern verhindert und Entzündungen vorbeugt.   ...
(Date:9/1/2015)... 2015 Prostate cancer is the second ... men. One in seven men will be diagnosed ... are diagnosed annually. That said, not every diagnosis ... new technique, MRI Fusion Biopsy, to more accurately ... only the affected areas and monitoring areas ...
(Date:9/1/2015)... ... September 01, 2015 , ... VetStem Biopharma announces new ... facet joint problems can be caused by injuries and abnormalities of the cervical ... roots or of the spinal cord itself. This can manifest itself as any ...
(Date:9/1/2015)... , Sept. 1, 2015   Medfusion, ... facilitating the relationship between doctors and patients, today ... Durham, N.C. -based venture capital firms. ... and business association with Bull City Venture Partners ... , Medfusion Founder and Executive Chairman. "Both firms, ...
Breaking Biology Technology:Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3
... , Introduction ... by a defective electron-galvanizing (EV) bath line. Because a ... to productivity, quality, and identification of errors, a detailed ... and contribute to selecting the best solution. Both downtime ...
... Reduced-Volume Samples , 20 L, 50 L, ... <br ,>enzymes polymers amino acids ,<P ,> ... <P ,>Samples can be valuable. Either you dont want to ... which to start. Biological proteins and enzymes, for example, are ...
... , ... Ph.D., PerkinElmer Life Sciences, Inc. , ... of DNA microarrays in scientific research and drug discovery has become very ... vast majority of the true drug targets, there has been a fast ...
Cached Biology Technology:Characterizing galvanizing baths 2Characterizing galvanizing baths 3New Tools for Making and Processing Protein Microarrays. 2New Tools for Making and Processing Protein Microarrays. 3New Tools for Making and Processing Protein Microarrays. 4New Tools for Making and Processing Protein Microarrays. 5New Tools for Making and Processing Protein Microarrays. 6New Tools for Making and Processing Protein Microarrays. 7New Tools for Making and Processing Protein Microarrays. 8New Tools for Making and Processing Protein Microarrays. 9
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
(Date:8/5/2015)... Transparency Market Research has released ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... is forecast to reach US$ 2,671.8 Mn by 2022. ... systems by civil and government agencies. This is majorly ... activities across the globe that would elevate the demand ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... - When a blood vessel clogs up, a localized deficiency ... working with mice, VIB scientists connected to the Katholieke Universiteit ... hypoxia from dying. The muscles seem to adapt to the ... animals also use when hibernating, but that has remained a ...
... Scripps Institution of Oceanography at UC San Diego has ... processes inside a marine organism that creates a natural ... The finding could lead to new applications of the ... team led by Bradley Moore, a professor with UCSDs ...
... State University will battle for the BCS National College ... if the game was held in the Louisiana wetlands ... wetlands are being lost at the rate of approximately ... this rapid destruction, the two universities joined forces in ...
Cached Biology News:Medical breakthrough for organ transplants and cardiovascular diseases by Flemish researchers 2Researchers uncover key trigger for potent cancer-fighting marine product 2LSU and Ohio State battle on football field, collaborate in research field 2
... C-1-tetrahydrofolate synthase, ... [Includes: Methylenetetrahydrofolate dehydrogenase ... cyclohydrolase (EC 3.5.4.9); ... 6.3.4.3)]. [Source:Uniprot/SWISSPROT;Acc:P11586] ...
...
recombination at attR1 and attR2 sites...
... Conjugate, 2 ml. Streptavidin ... molecules for use in ... hybridization applications.High specificity reagents. ... & Detection, Protein Labeling ...
Biology Products: